Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Distant metastases evaluable by radionuclide bone scan, CT scan, or magnetic resonance imaging (MRI) within the past 28 days * Evidence of progressive disease during androgen-deprivation therapy (including a trial of antiandrogen-withdrawal therapy), as defined by ≥ 1 of the following criteria: * Progressive measurable disease using conventional solid tumor criteria * Bone scan progression, defined as ≥ 2 new lesions on bone scan * Increasing PSA, defined as ≥ 2 consecutive rising PSA values over a reference value taken ≥ 1 week apart (the third PSA value must be greater than the second PSA value, if not, a fourth PSA value must be greater than the second PSA value) * Castrate levels of serum testosterone (i.e., ≤ 50 ng/dL) * No known brain metastases * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 OR Karnofsky PS 70-100% * Life expectancy \> 6 months * Leukocytes ≥ 3,000/μL * Absolute neutrophil count (ANC) ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Hemoglobin ≥ 9 g/dL * Total bilirubin ≤ 2 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN * Serum creatinine ≤ 1.5 times ULN * Creatinine clearance ≥ 50 mL/min * Able to adhere to the study visit schedule and other study requirements * Fertile patients must use effective contraception before, during, and for 3 months after completion of study treatment * Adequate lung function (pulmonary function test ≥ 70% for diffusion capacity of the lung for carbon monoxide \[DLco\]) * No poorly controlled diabetes mellitus * Patients with a history of diabetes are eligible provided their blood glucose is normal (i.e., fasting blood glucose \< 120 mg/dL or \< ULN) and they are on a stable dietary or therapeutic regimen * No other malignancy within the past 3 years except for treated basal cell or squamous cell carcinoma of the skin or superficial transitional cell carcinoma of the bladder * No uncontrolled major illness including, but not limited to, any of the following: * Active infection, including human immunodeficiency virus (HIV) infection or viral hepatitis * Symptomatic congestive heart failure (class III or IV) * Unstable angina pectoris * Myocardial infarction or acute coronary syndrome within the past year * Serious cardiac arrhythmia * Significant lung disease * Major psychiatric illness * No other concurrent anticancer agents or treatments * No prior chemotherapy, except for neoadjuvant chemotherapy * No prior anti-insulin-like growth factor receptor (IGFR) agents or mammalian target of rapamycin (mTOR) inhibitors * No prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy * Prior standard-dose radiotherapy to the pelvis for prostate cancer and/or additional external-beam radiotherapy to metastatic sites allowed * More than 4 weeks since prior surgery, radiotherapy, combined androgen blockade (excluding single-agent gonadotropin releasing-hormone agonists/antagonists), or investigational therapies * No concurrent second-line hormonal agents, including ketoconazole, diethylstilbestrol, other estrogen-like agents, or finasteride * No concurrent corticosteroids unless patient is on a stable maintenance dose of hydrocortisone (≤ 30 mg/day) for ≥ 3 months